Investor Overview


Corporate Profile

Tocagen is a clinical-stage, cancer-selective gene therapy company developing first-in-class, broadly applicable product candidates designed to activate a patient’s immune system against their own cancer from within. Tocagen is currently studying its lead product candidate, Toca 511 & Toca FC, in a Phase 3 clinical trial for the treatment of patients with recurrent high grade glioma (HGG), a type of brain cancer with limited treatment options. Toca 511 & Toca FC has been granted Breakthrough Therapy Designation for the treatment of patients with recurrent HGG by the FDA, and PRIME (PRIority MEdicines) designation by the European Medicines Agency.
Webcast ImageWebcast
Stifel Nicolaus Healthcare Conference  (Replay)
11/14/18 at 11:00 a.m. ET
Stifel Nicolaus Healthcare Conference
Wednesday, November 14, 2018 11:00 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Webcast ImageWebcast
Evercore ISI Biopharma Catalyst/Deep Dive Conference (Live)
11/27/18 at 4:35 p.m. ET
Evercore ISI Biopharma Catalyst/Deep Dive Conference
Tuesday, November 27, 2018 4:35 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
NASDAQ GS TOCA (Common Stock)
$11.87 - 0.31
Stock chart for: TOCA.O.  Currently trading at $11.87 with a 52 week high of $15.80 and a 52 week low of $7.52.
11/14/18 4:00 p.m. ET
Data provided by Nasdaq. Minimum 15 minutes delayed.

Recent News

View All  

Tocagen Reports Third Quarter 2018 Financial and Business Results

11/08/18

Read More

Tocagen to Participate in Investor Conferences in November

11/07/18

Read More

Tocagen to Present Updated Data from Clinical and Preclinical Studies at Three Scientific and Medical Conferences

11/06/18

Read More